
May 7, 2026
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics
Roche has announced a definitive merger agreement to acquire PathAI, aiming to enhance AI-driven diagnostics in pathology. This strategic acquisition marks a significant evolution in Roche's commitment to digital pathology and AI technologies. PathAI, known for its innovative solutions in pathology laboratories and the biopharma sector, has been a partner of Roche since 2021. Their collaboration has intensified over the years, particularly with the development of AI-enabled companion diagnostic









